Overview of neonatal respiratory distress

Running head:NEONATAL RESPIRATORY DISEASES
NEONATAL RESPIRATORY DISEASES
Name of the student
Name of the university
Author note

1
NEONATAL RESPIRATORY DISEASES
Introduction
In premature newborns born before 32 weeks of pregnancy, neonatal respiratory
diseases are normal because their lungs are unable to produce enough surfactant, a foamy
fluid that keeps the lung completely extended. There are various symptoms of pneumonia and
sepsis, including the usual signs of respiratory distress as well as temperature instability.
Pneumonia is an inflammatory lung condition that mainly affects the small air sacs known as
alveoli. Pneumonia is the world's most common cause of death in infants, accounting for 15%
of all deaths of children under the age of 5. This study will shed light on the contrasting
character of research questions, sample population, and limitations of the study. It will
include the efficiency of VAP prevention bundle and budesonide nebulization, the impact of
ambroxol budesonide, palivizumab, zinc supplements and physical chest exercise on neonatal
pneumonia. A brief conclusion along with the prospective for further study, will be provided.
Comparison of Research Questions
Article 1 has focused its research on the impact of palivizumab against RSV infection
instead of studying the prevalence rate of pneumonia in neonatal admitted in the neonatal
intensive care unit, which has been in article 2 (Yuan et al., 2016). The effect of palivizumab
on the neonatal admitted in the intensive care unit has not been deduced. According to a
study in Article 3, it has been seen that zinc supplements do not enhance much of the clinical
results (Abdelbasset & Elnegamy, 2015). On the contrary, it has been seen in Article 4, that
physical chest exercise can enhance the condition of pediatrics hospitalized due to
pneumonia. One of the studies focused on neonatal pneumonia of aerosol inhalation in
addition to ambroxol budesonide, whereas the other study shifts its focus on the impact of
ambroxol inhalation on neonatal pneumonia. Two contrary results while researching on
ventilator-associated pneumonia say Budesonide nebulization show effective result in

2
NEONATAL RESPIRATORY DISEASES
treating VAP whereas the other study focused on VAP prevention bundle to increase the
efficiency of infection control.
Comparison of Sample Populations
All of the studies were done on infants with pneumonia with different population
sizes according to the experiment. In article 1, a random population of infants was considered
(Bollani et al., 2015) whereas in Article 2, 96 infants were subjected to zinc supplement. The
sample size for Article 3 is around 50 children between the age of 29 days to 5 years have
been taken. On the contrary, for the VAP prevention bundle, neonates with mechanical
ventilation for ≥ 48hrs or NICU of children Hospital of Zagazig University were chosen for
the experiment (Azab et al., 2015). In Article 5, NICU of Bangabandhu Sheikh Mujib
Medical University or 94 neonates have been chosen. 80 newborns with neonatal pneumonia
were targeted to know the effect and the process of ambroxol inhalation, whereas 45
newborns and 66 infants were considered to identify the effect of budesonide nebulization
and ambroxol conjugated budesonide aerosol respectively on neonatal affected with
pneumonia.
Comparison of the Limitations of the Study
According to Article 1, palivizumab have effective potential on RSV infected disease,
but the effect of palivizumab does not stand well in patients with immunodeficiency.
Moreover, the proper sample size is not mentioned and resistance is considered to be a
constant factor linked to the unauthorized use of antibiotics. Patients admitted to the
emergency departments are especially neonates with low immunity. It is the liability of health
care facilities to use evidence-based approaches in the administration of neonates '
medication. Centered patient care is key in neonatal pneumonia management which limited
the study of Article 2. However, Article 3, lacks clinical evidence for the positive impact of
pediatrics, chest physical therapy has been used to treat pediatrics hospitalized with